Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>We compared the incremental effects of adding acceptance and commitment therapy (ACT) to pharmacological treatment as usual (TAU) in a sample of patients with high frequency episodic migraine without aura (HFEM), assessing impact on a spectrum of measures across multiple domains.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Patients with HFEM are at risk of developing chronic migraine and medication overuse headache. ACT has been shown to be effective for the treatment of various chronic pain conditions, but little attention has been given to its therapeutic value in the management of recurring headaches.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>In this single-blind (masking for outcome assessor), open-label, randomized clinical trial, 35 patients with HFEM, with a monthly headache frequency ranging from 9 to 14 days, were recruited at the headache center of C. Besta Neurological Institute and randomized to either TAU (patient education and pharmacological prophylaxis; <i>n</i> = 17) or TAU + ACT (<i>n</i> = 18). Patients assigned to the combined treatment arm additionally received six 90-min weekly group sessions of ACT therapy and two supplementary "booster" sessions. All patients were on a stable course of prophylactic medication in the 3 months prior to initiating either treatment. Monthly headache frequency served as the primary outcome measure, with all other data collected being considered as secondary measures (medication intake, disability, headache impact, anxiety and depression, catastrophizing, allodynia, cognitive inflexibility, pain acceptance, mindful attention and awareness). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>A total of 35 patients were enrolled: 17 randomized to TAU, of whom three dropped out, and 18 to TAU + ACT (no dropouts in this group). Headache frequency and medication intake decreased in both groups over 12 months, with patients in the TAU + ACT group showing statistically significant reduction earlier, that is, by month 3. Headache frequency was reduced by 3.3 days (95% CI: 1.4 to 5.2) among those randomized to ACT + TAU, whereas it increased by 0.7 days (95% CI: −2.7 to 1.3) among those randomized to TAU only (<i>p</i> = 0.007, partial <i>η</i><sup>2</sup> = 0.21), the difference being 4 days (95% CI: 1.2 to 6.8). Medication intake was reduced by 4.1 intakes (95% CI: 2.0 to 6.3) among those randomized to ACT + TAU and by 0.4 intakes (95% CI: −1.8 to 2.5) among those randomized to TAU only (<i>p</i> = 0.016; partial <i>η</i><sup>2</sup> = 0.17), the difference being 3.8 intakes (95% CI: 0.7 to 6.8). At 6 and 12 months, the variations were not different between the two groups for headache frequency and medication intake. The opposite was found for measures of headache impact and pain acceptance, where the differences over time favored patients allocated to TAU. Both groups improved with regard to measures of disability, anxiety and depression, catastrophizing, and cognitive inflexibility, whereas measures of allodynia and pain acceptance were stable over time. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Our preliminary findings indicate that supplementing TAU with ACT can enhance the main clinical outcomes, namely headache frequency and medication intake of patients with HFEM.</p></section>

High-frequency episodic migraine: Time for its recognition as a migraine subtype?

Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study

Hallmarks of primary headache: part 1 – migraine

European headache federation consensus on the definition of resistant and refractory migraine

Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives

Time and headache: Insights into timing processes in primary headache disorders for diagnosis, underlying pathophysiology and treatment implications

Future targets for migraine treatment beyond CGRP

Altered Neuromagnetic Activity in the Default Mode Network in Migraine and Its Subgroups (Episodic Migraine and Chronic Migraine)

Migraine - a borderland disease to epilepsy: near it but not of it

Patterns of habituation and clinical fluctuations in migraine

Genetic mechanisms underlying local spontaneous brain activity in episodic migraine

Health equity, care access and quality in headache – part 1

Migraine chronification is associated with beta-band connectivity within the pain-related cortical regions

Headache frequency associates with brain microstructure changes in patients with migraine without aura

Insights into Chronic Migraine and Medication Overuse Headache with Electrophysiological Analysis

Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation

Acute migraine in the Emergency Department: extending European principles of management

Multilevel clinical fingerprinting: uncovering longitudinal changes in the functional connectome of the brain along the migraine cycle

Episodic Migraine With and Without Aura: Key Differences and Implications for Pathophysiology, Management, and Assessing Risks

Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study

Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study